Serology Testing Market Report (2022 to 2030)

Pune, Oct. 17, 2022 (GLOBE NEWSWIRE) — The Global Serology Testing Market is should clock $7.6 billion by 2030. The market is driven by rising HIV transmission rates, rise in COVID-19 cases, rise in hepatitis B and C patients, and the threat of novel viruses. Additionally, increasing affordability of testing, accurate diagnosis, and introduction of new diagnostic methodologies are contributing to the growth of the global serology testing market.

Excerpts from “Competitive Landscape”

The key players operating in the global serological testing market are:

  • Abbott Laboratories Inc.
  • Quidel Company
  • Beckman Coulter, Inc.
  • Becton Merck KGaA
  • bioMérieux SA
  • Grifols, SA
  • DiaSorin SpA
  • Eurofins Scientific
  • F. Hoffmann-La Roche SA
  • Mylab Discovery Solutions Pvt. ltd
  • Tulip Diagnostics Ltd. (Perkin Elmer Inc.)
  • Siemens Healthineers AG
  • Sysmex Company
  • Becton
  • Dickinson & Co.
  • Thermo Fisher Scientific Inc.

Download PDF Brochure of Serology Testing Market Size – Impact of COVID-19 and Global Analysis with Strategic Developments on: https://growthplusreports.com/inquiry/request-sample/serological-testing-market/7872

Growth engines

HIV is a human immunodeficiency virus, typically attacking immune cells that fight antigens and infections. Acquired immunodeficiency syndrome (AIDS) is an advanced stage HIV infection in which the immune system is severely damaged. Infected people are likely to develop illnesses and contract infections at a higher rate. From time to time, a diagnosis is necessary to monitor the viral load in these patients. Diagnosis of HIV is made by rapid antigen test, Western blot method, ELISA test and RTPCR. According to the Centers for Diseases Control and Prevention, in 2019 nearly 34,800 new cases of HIV were recorded in the United States. About 80% of cases of HIV transmission are due to lack of regular care or to people who do not know they are HIV-positive. It is estimated that in 2019, approximately 1,189,700 people in the United States were HIV positive. The high rate of HIV transmission and the growing number of HIV-infected patients are fueling the serology testing market.

Serological tests are used to detect antibodies or antigens. Antigens are foreign substances that are mainly responsible for causing diseases. When the body comes into contact with an antigen, the immune system releases antibodies as a defense mechanism and attempts to neutralize the antigen. In serological tests, these antibodies and antigens are validated to diagnose a specific disease and condition, which further helps doctors in giving proper medical treatment. Serological tests are performed by various methods such as hemagglutinin inhibition tests, enzyme immunoassays (ELISA), flocculation tests, neutralization tests and chemiluminescence immunoassays.

The global serological testing market has been analyzed from five different perspectives – product, Technology, application, end user and region.

Excerpts from “Product”

The Global Serology Testing Market has been segmented into:

  • instruments (immunoassay analyzers, ELISA analyzers, ELFA analyzers and POC analyzers)
  • reagents and consumables (ELISPOT reagents and kits, ELISA reagents and kits, Western Blot reagents and kits, rapid test reagents and kits)

Reagents and consumables are dominating the global serology testing market owing to the affordability of the tests and the high consumption of reagents by research institutes and diagnostic laboratories.

Inquiry before buying: https://growthplusreports.com/inquiry/before-buying/serological-testing-market/7872

Excerpts from “By technology”

The global market for serological tests based on technology has been segmented into:

  • Enzyme immunoassay (ELISA)
  • Western Blot
  • Nucleic acid test (NAT)
  • Microparticle Chemiluminescence Immunoassay (CMIA)
  • Lateral flow test

ELISA is the global market leader in serology tests due to short test turnaround time, cheap and affordable reagents, long regent shelf life, high number of disease screenings infectious, high specificity, high sensitivity and inexpensive ELISA analyzers. Additionally, advancements in technology, high precision screening, less complex steps required for execution, and numerous key players are driving the growth of ELISA testing segment.

Excerpts from ‘Segmentation by region’

The Global Serology Testing Market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

North America has dominated the global market for serological tests. North America’s large share in the global serology testing market is attributed to the recent outbreak of COVID-19, high awareness of communicable diseases, and prevalence of infectious diseases. In addition, high health expenditure, developed infrastructure, favorable government policies, rapid adoption of new technologies and rapid approval of new serology tests are contributing to the growth of the North American serology testing segment.

Contents

  1. INTRODUCTION
    1. Market ecosystem
    2. Schedule under study
      1. Historical years – 2020
      2. Base year – 2021
      3. Planned years – 2022 to 2030
    3. Currency used in the report
  2. RESEARCH METHODOLOGY
    1. Research approach
    2. Data collection methodology
    3. Information source
      1. Secondary sources
      2. Primary sources
    4. Market estimation approach
      1. From bottom to top
      2. From top to bottom
    5. Market Forecast Model
    6. Limits and assumptions
  3. PREMIUM OVERVIEW
    1. Current market trends (COVID-19 outlook)
    2. Key players and competitive positioning (2021)
  4. MARKET DYNAMICS
    1. Drivers
    2. Constraints/Challenges
    3. Opportunities
  5. GLOBAL SEROLOGICAL TESTING MARKET – ANALYSIS AND FORECAST, BY PRODUCT
    1. Instruments
    2. Reagents & Consumables
  6. GLOBAL SEROLOGICAL TESTING MARKET – ANALYSIS AND FORECAST, BY TECHNOLOGY
    1. Enzyme immunoassay (ELISA)
    2. Nucleic acid test (NAT)
    3. Microparticle Chemiluminescence Immunoassay (CMIA)
    4. Lateral flow test
  7. GLOBAL SEROLOGICAL TESTING MARKET – ANALYSIS AND FORECAST, BY APPLICATION
    1. Blood group detection
    2. COVID-19[feminine]
    3. Dengue fever
    4. torch test
    5. Hepatitis B
    6. Hepatitis C
    7. HIV
    8. Malaria
    9. Syphilis
    10. Others

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Fueled by free analyst hours and expert interviews with every report
  • Comprehensive quantitative and qualitative information at segment and sub-segment level
  • Trends and perspectives of the impact of Covid 19
  • Granular information at global/regional/country level
  • In-depth insights into market dynamics (drivers, restraints, opportunities) and business environment
  • Global coverage of the competitive landscape
  • Winning imperatives
  • Comprehensive coverage of “strategic developments” recorded by major market players

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment
  • Pricing information
  • Customer evaluation
  • Analysis of investments and initiatives
  • ‘Company Profile’ of key players

Purchase a premium copy of Serology Testing Market Growth Report (2022-2030) directly at: https://growthplusreports.com/checkout?_token=fyym7zXGiMgs4dQvOtyo7xoscTLw0m1CLbTzsEWp&report_id=7872&license=Single

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of the EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth Plus portfolio of services leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable solutions and breakthroughs that set them up for future growth and success.

We have been recognized by the prestigious CEO Magazine as “The Most Innovative Market Research Company in the Healthcare Market of 2020.


        
Back To Top